Weekly Investment Analysts’ Ratings Updates for Nurix Therapeutics (NRIX)

Several brokerages have updated their recommendations and price targets on shares of Nurix Therapeutics (NASDAQ: NRIX) in the last few weeks:

• 1/29/2026 – Nurix Therapeutics had its price target raised by analysts at Stifel Nicolaus from $33.00 to $35.00. They now have a “buy” rating on the stock.
• 1/29/2026 – Nurix Therapeutics had its price target lowered by analysts at Wells Fargo & Company from $30.00 to $29.00. They now have an “overweight” rating on the stock.
• 1/29/2026 – Nurix Therapeutics had its price target raised by analysts at Piper Sandler from $32.00 to $35.00. They now have an “overweight” rating on the stock.
• 1/29/2026 – Nurix Therapeutics had its price target raised by analysts at HC Wainwright from $31.00 to $32.00. They now have a “buy” rating on the stock.
• 1/29/2026 – Nurix Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $28.00 to $30.00. They now have an “outperform” rating on the stock.
• 1/29/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $30.00 price target on the stock.
• 1/29/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
• 1/22/2026 – Nurix Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/8/2026 – Nurix Therapeutics was given a new $36.00 price target on by analysts at Morgan Stanley. They now have an “overweight” rating on the stock.
• 12/16/2025 – Nurix Therapeutics had its price target raised by analysts at Wells Fargo & Company from $21.00 to $30.00. They now have an “overweight” rating on the stock.
• 12/10/2025 – Nurix Therapeutics had its price target raised by analysts at HC Wainwright from $28.00 to $31.00. They now have a “buy” rating on the stock.
• 12/10/2025 – Nurix Therapeutics had its price target raised by analysts at Mizuho from $24.00 to $30.00. They now have an “outperform” rating on the stock.
• 12/9/2025 – Nurix Therapeutics had its price target raised by analysts at BTIG Research from $27.00 to $30.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Nurix Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 3,661 shares of the business’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $60,772.60. Following the completion of the sale, the chief financial officer owned 45,427 shares of the company’s stock, valued at approximately $754,088.20. The trade was a 7.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gwenn Hansen sold 4,895 shares of the stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $81,257.00. Following the transaction, the insider directly owned 83,672 shares in the company, valued at $1,388,955.20. The trade was a 5.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.40% of the stock is owned by company insiders.

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.